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Metabolite Profiles into Metabolic FluxesSonia Cortassa,1 Viviane Caceres,1 Lauren N. Bell,2 Brian O’Rourke,1 Nazareno Paolocci,1 and Miguel A. Aon1,*
1Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and 2Metabolon, Inc., Durham, North CarolinaABSTRACT We describe a believed-novel procedure for translating metabolite profiles (metabolome) into the set of metabolic
fluxes (fluxome) from which they originated. Methodologically, computational modeling is integrated with an analytical platform
comprising linear optimization, continuation and dynamic analyses, and metabolic control. The procedure was tested with
metabolite profiles obtained from ex vivo mice Langendorff-heart preparations perfused with glucose. The metabolic profiles
were analyzed using a detailed kinetic model of the glucose catabolic pathways including glycolysis, pentose phosphate
(PP), glycogenolysis, and polyols to translate the glucose metabolome of the heart into the fluxome. After optimization, the ability
of the model to simulate the initial metabolite profile was confirmed, and metabolic fluxes as well as the structure of control and
regulation of the glucose catabolic network could be calculated. We show that the step catalyzed by phosphofructokinase
together with ATP demand and glycogenolysis exert the highest control on the glycolytic flux. The negative flux control exerted
by phosphofructokinase on the PP and polyol pathways revealed that the extent of glycolytic flux directly affects flux redirection
through these pathways, i.e., the higher the glycolytic flux the lower the PP and polyols. This believed-novel methodological
approach represents a step forward that may help in designing therapeutic strategies targeted to diagnose, prevent, and treat
metabolic diseases.INTRODUCTIONConsiderable effort has been invested in whole-genome/
proteome screenings to detect genetic loci contributing to
the susceptibility of complex human diseases such as dia-
betes and cancer. As a result, gene/protein changes have
been cataloged and with the help of systems biology
approaches are now transforming medical and clinical prac-
tice (1). Yet, articulating ‘‘omics’’ technologies into quanti-
tative and physiologically meaningful mechanisms remains
a challenging (2–4) but promising frontier to explore in the
attempt to effectively combat chronic diseases such as
diabetes.
The complex nature of a disease often originates from
impairment of several steps in different biochemical path-
ways. For instance, the net effect of an inborn error of meta-
bolism on the organ and organism levels is the alteration of
one or more metabolite fluxes (5). A metabolic flux is
defined as the rate (i.e., molar per unit time) at which metab-
olites are converted or transported between compartments in
a network of biochemical reactions. Ultimately, it is the
concept of metabolic flux that is crucial in the translation
of genotype and environmental factors into a healthy or
disease phenotype.Submitted June 25, 2014, and accepted for publication November 14, 2014.
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0006-3495/15/01/0163/10 $2.00In systemic disorders like diabetes, a whole network of
metabolic fluxes is drastically altered. Metabolic remodel-
ing occurs at the level of the genome, transcriptome, and
proteome, including posttranslational modifications (2)
but, in the end, enzymatic activities and the resulting metab-
olite profiles will reflect all those changes. Thus, in princi-
ple, a metabolite profile could be translated into the set of
fluxes that gave rise to the metabolome.
The set of metabolic fluxes, or fluxome, represents a
dynamic picture of the phenotype, inasmuch as it captures
the metabolome in its functional interactions with the envi-
ronment and the genome (4,6). As such, the fluxome inte-
grates information on several cellular processes, and hence
it is a unique phenotypic signature of cells (2). A main
advantage of fluxomics over genomics and proteomics is
that it is based on information from metabolites, which
are far fewer than genes or proteins (7). For instance, in
the mouse there are ~600 detectable low-molecular-weight
intermediates (8), whereas there are ~10,000 proteins and
~22,000 protein-encoding genes (4).
For systemic metabolic remodeling, as occurs in diabetes
or cancer, metabolic fluxes become crucial for quantitative
interpretation (5). For example, the cardiac redox status
plays a relevant role in diabetic cardiomyopathy (9).
The myocardial redox balance can change in response to
hyperglycemia, a prevalent condition in diabetic patients,
due to redirection of glucose catabolic fluxes through
the NADPH-consuming (polyol) or NADPH-generating
(pentose-phosphate (PP)) pathways, respectively. To assesshttp://dx.doi.org/10.1016/j.bpj.2014.11.1857
164 Cortassa et al.the extent of flux through different pathways occurring
simultaneously, a quantitative systems biology approach is
needed.
Herein, we introduce a believed-novel metabolomic-
fluxomic procedure that enables the translation of high
throughput metabolite profiles (metabolome) into the flux-
ome, from which the profiles emerged. Importantly, this
methodology also allows one to determine the structure of
control and regulation of the fluxome. Our approach consists
of the combination of an analytical platform—comprising
several integrated quantitative methodologies—with a
detailed computational kinetic model that accounts for reg-
ulatory interactions. This analytical procedure, spanning
from metabolome to fluxome, is applicable to any metabolic
system that can be described by kinetic modeling. The
advantage of our approach over existing methodologies
(10) is that it incorporates regulatory information (e.g.,
effectors, feedbacks) crucial for understanding dynamic sys-
tems. Heart function is an ideal prototypic system to test the
usefulness of the approach proposed herein. Because the
heart is constantly changing in response to energy demand,Polyols - Glycolysis   - Glycogenolysis – Pentose Phosphat
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Biophysical Journal 108(1) 163–172the choice of kinetic modeling is justified because it can ac-
count for time-dependent behavior. Applying our procedure
and combining metabolic flux estimation with cardiac work
measurement will lend insight into mechanisms underlying
contractile impairment.MATERIALS AND METHODS
Computational model description
Kinetic modeling of glycolytic, glycogenolytic, polyol,
and PP pathways
The computational model consists of a detailed kinetic scheme of glucose
catabolism comprising glycolysis, glycogenolysis, PP, and polyol (marked
in red) pathways (Fig. 1 and see Section S1 in the Supporting Material). De-
picted also are the exchanges with the extracellular medium including input
(glucose, O2) and output (lactate, fructose, xylitol) fluxes (light-blue
arrows).
The model rate equations account for the effect of known regulatory
interactions and effectors, e.g., ATP for glucose 6 phosphate dehydrogenase
(G6PDH), AMP for phosphofructokinase (PFK), or GDP for pyruvate
kinase (PK). In addition to the metabolite concentrations the rate ofe 
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FIGURE 1 Main glucose degradation pathways
in the heart. The glycolytic, glycogenolytic,
pentose phosphate (PP) and polyol pathways taken
into account by the computational kinetic model
are displayed, along with extracellular exchanges
comprising input (glucose, O2) and output (lactate,
fructose, xylitol) fluxes (light-blue arrows). (Red)
Intermediates of the polyol pathway. Metabolites:
Glc, glucose; Hexose 6P, accounts for Glucose
6-phosphate plus Fructose 6-phosphate; G3P,
glyceraldehyde 3-phosphate; 1,3-BPG, 1,3-biphos-
phoglycerate; 3PG, 3-phophoglycerate; PEP,
phosphoenolpyruvate; Pyr, pyruvate; Lac, lactate;
Glc1P, glucose 1-phosphate; (Maltose)n, maltooli-
gosaccharides (maltose, malto-triose, -tetraose,
-hexaose, etc.); 6PGluc, 6-phosphogluconate;
Ru5P, ribulose 5-phosphate; R5P, ribose 5-phos-
phate; X5P, xylulose 5-phosphate; E4P, erythrose
4-phosphate; S7P, sedoheptulose 7-phosphate.
Enzymes: ALR, aldose reductase; SoDH, sorbitol
dehydrogenase; HK, hexokinase; GP, glycogen
phosphorylase; PGM, phosphoglucomutase; HK,
hexokinase; PFK, phosphofructokinase 1; ALD,
aldolase; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; PGK, phosphoglycerate kinase;
ENOL, enolase; PK, pyruvate kinase; LDH,
lactate dehydrogenase; G6PDH, glucose 6-phos-
phate dehydrogenase; 6PGDH, 6-phosphogluco-
nate dehydrogenase; R5PI, Ribose 5-phosphate
isomerase; Transket, transketolase; RuPE, Ribu-
lose-phosphate 3-epimerase; Tkt, transketolase;
TAL, transaldolase. To see this figure in color, go
online.
From Metabolomics to Fluxomics 165pyruvate transport into mitochondria was provided as input. The rate at
which pyruvate is consumed by mitochondria was derived from the rate
of oxygen consumption reported for ex vivo heart preparations (11),
analyzed under similar substrate conditions without external workload as
in Langendorff-perfused hearts. Two moles of O2 will be reduced to H2O
in the respiratory chain per mol of pyruvate consumed by mitochondria.
Next, we describe each pathway accounted for by the model, and in a
more detailed manner all rate equations are included in the Supporting
Material.
Glycolysis
The model of glycolysis was based on Lambeth and Kushmerick (12), who
describe the carbohydrate degradation pathway in mammalian skeletal
muscle (see Section S2 in the Supporting Material). This model starts
from glucose-6-phosphate and takes into account the steps down to lactate
formation, excluding hexokinase (HK). The rate expressions and kinetic
parameters of HK are from Lueck and Fromm (13) (see Eq. S2). We
have introduced an expression to model glucose transport based on a Fick’s
law of diffusion, thus dependent on the concentration gradient across the
plasma membrane (Eq. 1).
Important regulatory steps are described in the model, such as the rate
expression of the following: 1) phosphofructokinase, which includes its
inhibition by AMP and ATP, its dependence on substrates ATP and fructose
6P, and products ADP and fructose 1,6-bisphosphate (see Eq. S3); and 2)
glyceraldehyde 3-phosphate dehydrogenase, which obeys a reversible
reaction accounting for hyperbolic kinetic dependence on glyceraldehyde
3-phosphate and biphosphoglycerate, and negative cooperativity by both
NAD and NADH (see Eq. S5) (14).
Glycogenolysis
The glycogen degradation pathway comprises debranching enzymes,
phosphorylase a and b, and phosphoglucomutase enzymes (see Eqs. S10–
S12). The enzymatic rate expressions were based on the skeletal muscle
model (12).
PP pathway
The oxidative and nonoxidative branches of the PP pathway were taken into
account by the model (see Eqs. S14–S20 in Section S2.3 in the Supporting
Material). The rate expressions for each of the enzymatic steps involved in
the PP pathway were based on Nishino et al. (15). These authors parame-
terized their model according to data from McIntyre et al. (16). G6PDH,
the first enzyme of the pathway, was parameterized according to Buckwitz
et al. (17) and includes ATP inhibition (see Eq. S14).
Polyols
Activation of the polyol pathway may have adverse consequences for heart
function (18). Hyperglycemia (19) and sustained b-adrenergic stimulation
are both known to stimulate polyols (20). The sorbitol route included fruc-
tose synthesis by sorbitol dehydrogenase, in addition to aldose reductase
(see Section S2.4 in the Supporting Material). The rate expression and
kinetic parameters of aldose reductase were derived from the work of
Grimshaw et al. (21) with kinetic data from Kubiseski et al. (22) and Halder
and Crabbe (23) (see Eq. S21). Sorbitol and xylitol dehydrogenases were
modeled following the kinetic characterization and parameters determined
by Karacaoglan and Ozer (24) and O’Brien et al. (25) (see Eqs. S22
and S23).
ATPase, nonglycolytic NADH consumption, NADPH
consumption, and polyol transport
To achieve steady-state behavior, the model formulation also includes rate
expressions accounting for the consumption of adenine and pyridine nucle-
otides and polyol excretion. We assumed that the kinetic behavior of those
processes can be represented by hyperbolic functions (see Eqs. S24–S28).The equation representing ATP hydrolysis was considered irreversible,
unlike those corresponding to NAD(P)H consumption, which were modeled
as reversible reactions.Integrated analytical platform
Kinetic modeling of metabolic networks, and their
continuation and dynamic analyses
Other than steady-state fluxes (26–29), a realistic representation of transient
behavior requires detailed kinetic modeling including mechanistic regulato-
ry information such as flux regulation, e.g., by substrate and product inhi-
bition/activation. Kinetic models can also accommodate the nonlinear
behavior imparted by feedback and feedforward regulatory mechanisms.
Continuation analyses of nonlinear kinetic models allow the exploration
of their qualitative as well as quantitative behavior (30–32).
Computer model simulations as a function of time or analyzed at the
steady state were carried out with MATCONT (sourceforge.net/projects/
matcont), a package designed for continuation analysis implemented in
the software MATLAB (The MathWorks, Natick, MA) (33,34). The kinetic
model of glucose catabolism is represented by a system of ordinary differ-
ential equations (ODEs) (see Section S1 in the Supporting Material), which
was computed as a function of time until a steady state is reached, i.e., when
the state variable derivatives are <1  1010. MATLAB’s built-in solver,
ODE15s, designed for stiff equations, was used as integrator. This ODE
solver adjusts the integration step size during the computation.
Linear optimization of Vmax in the kinetic model
To quantify metabolic fluxes from metabolite profiles using the kinetic
model, we assume the validity of the association/dissociation affinity con-
stants determined in vitro for each of the enzymatic steps. Another assump-
tion is that the metabolite concentrations correspond to a steady state, which
is experimentally justified by whole heart analysis after 30 min perfusion
under specified conditions (see Preparation and Perfusion of Mouse
Hearts). Consequently, the Vmax of each enzyme is the only unknown
kinetic parameter subjected to optimization. Metabolic enzymes may
change their amounts after transcriptional-translational regulation, or after
posttranslational modifications, which are reflected by their Vmax values.
We used linear optimization (28,35) because the number of Vmax un-
knowns (one per step in the network) is larger than the number of metabo-
lites available from metabolomics, implying that the system is
underdetermined. Thus, instead of calculating a unique solution for the sys-
tem, we obtain a volume of possible solutions. This entails that we are able
to calculate a range of fluxes compatible with the given initial input, i.e.,
metabolites concentration profile and exchange fluxes with the extracellular
medium. This optimization procedure was inspired by the flux balance anal-
ysis developed by Savinell and Palsson (29). For optimization we proceed
to represent the rate of each step in the metabolic network by explicit rate
expressions that are, in all cases, a linear function of Vmax. The latter
assumption is required for applying linear optimization methods.
The method is based on the general equation
dx=dt ¼ S  vþ b; (1)
with dx/dt representing the vector of derivatives of the state variables (inter-
mediary metabolite concentrations); S is the stoichiometric matrix of size n
 m, with n and m being the number of metabolites and metabolic fluxes,
respectively; and b is the vector of transport and demand processes, e.g.,
biosynthesis. Finally, v stands for the vector rates expressed as the rate equa-
tion in the model with known kinetic parameters except for Vmax, which is
subjected to optimization. In the network analyzed herein (Fig. 1), n ¼ 19
and m ¼ 25; thus, the dimension of the solution space is mn ¼ 6.
Optimization of the linear algebraic system is performed with the Sim-
plex algorithm (implemented in MATLAB). Maximization of ATP synthe-
sis fluxes or minimization of redox consumption were used as objectiveBiophysical Journal 108(1) 163–172
TABLE 1 Comparison of experimental and model-simulated
metabolite concentrations
Metabolite Experimentala Model
Glucose (external) 11
Glucose (internal) 1.52 1.47
Maltosides 5.65 0.4 5.6
G1P 0.1635 0.004 0.15
F6P þ G6P 4.065 0.27 4.20
F1,6bP 0.0155 0.005 0.0147
G3P <0.01 0.009
1,3 DPG <0.01 6.6  104
3-PG 0.575 0.04 0.56
PEP <0.01 1.99  103
Pyruvate <0.01 8.5  103
Ru5P þ X5P 2.585 0.68 2.54
R5P 0.295 0.07 0.39
Sorbitol 0.675 0.32 0.65
Fructose 1.75 1.2 1.72
Xylitol 0.655 0.18 0.66
aExperimental and model-simulated concentrations are expressed in
mmol/L and experimental values are displayed as mean 5 SE (n ¼ 6).
166 Cortassa et al.functions to constrain the optimization procedure. In Table S24, we quan-
tify the impact of different objective functions on Vmax (Supporting
Material).
Analytical and numerical methods utilized
1. The function ‘‘linprog’’ from MATLAB (The MathWorks) was utilized
with the Simplex algorithm for optimization of Vmax values.
2. Within the volume of possible solutions, a solution was chosen in
order to corroborate that the system is able to reproduce the original
metabolite profile. The solution was calculated with the ‘‘linsolve’’ func-
tion from MATLAB using six of the maximal values of Vmax down-
stream in the metabolic network, e.g., VXDHmax;f , V
SoDH
max;f , V
LDH
max;ðf ÞðrÞ, and
ETK2, because they are relatively less interdependent as compared to
upstream ones.
After exploring several combinations of the optimized Vmax values, we
chose a solution that fulfilled two conditions: 1) Vmax > 0 for all enzyme
activities in the network, and 2) a solution that belongs to the hypervolume
of dimension 6 (see Section S2.2 in the Supporting Material).
With the solution at hand, i.e., the set of optimized Vmax values, we ran
computer simulations to reproduce the initial metabolite profile; once the
latter was simulated by the model at steady state, we were also able to
obtain the rate or flux through each individual step of the metabolic
network. We consider that the set of metabolic fluxes determined corre-
spond to one of the vertices of the volume of solutions corresponding to
the fluxome, as illustrated for a simpler system with a two-dimensional
solution space (see Fig. S1). To demonstrate the potential of the method,
linear algebra functions from the software MATLAB were utilized for
matrix calculations to quantitate the main rate-controlling and regulatory
steps of the metabolic network, as described next.
Quantifying control and regulatory steps in the metabolic
network
Metabolic control analysis quantifies the control in a metabolic pathway
through two types of coefficient: the flux (or metabolite concentration) con-
trol coefficient and the elasticity coefficient (4,36,37). In general terms,
‘‘control’’ is used to describe quantitatively the effect on flux produced by
a change in enzyme activity, whereas ‘‘regulation’’ denotes the modulation
of enzyme activity by effectors. In a quantitative sense, regulation refers to
how the flux of a pathway is modified through the effect on the rate of an
individual step by cellular or external factors, which may include interme-
diarymetabolite, ion concentrations, or pH, and is quantified by the response
coefficient. This coefficient measures the fractional change in flux, e.g.,
glycolysis, in response to a fractional change in an external or internal param-
eter A (e.g., an effector such as fatty acids) other than enzyme activity (37).
The method of Cortassa et al. (36) and Reder (38) was used to analyze
control and regulation of the biochemical network shown in Fig. 1. In addi-
tion to the flux and metabolite control coefficients, this method represents a
way to analyze, through the response coefficients the sensitivity of the
metabolic system to perturbations triggered by an internal change in the
system or to an environmental perturbation. The method has been exten-
sively described and validated in Cortassa et al. (36).
The analysis uses the stoichiometric matrix, which defines the structural
relationships between the processes and the intermediates participating in
the metabolic network, and the elasticity matrix, defined by the dependence
of each process in the network upon intermediates and effectors (e.g.,
metabolites, ions) included in the model (see Section S3 in the Supporting
Material). The elasticity matrix is obtained from the derivatives of the rate
expressions of individual processes with respect to each intermediate in the
metabolic network.
The following matrix relationships were used in the computation of flux
and metabolite concentration control coefficients (36),
C ¼ Idr  Dxv LðSrDxv LÞ1 Sr; (2)Biophysical Journal 108(1) 163–172G ¼  L ðSr Dxv LÞ1 Sr; (3)
withC andG referring to the matrices of flux- and metabolite-concentration
control coefficients, respectively; Idr is the identity matrix of dimension r,
the number of processes in the network under study; Dxv is the elasticity
matrix; Sr is the reduced stoichiometric matrix; and L is the link matrix
that relates the reduced- to the full-stoichiometric matrix of the system.
The stoichiometric matrix Sr is the same one used in the optimization
procedure described above, after eliminating redundant rows (see Section
S3 in the Supporting Material).Translating metabolite profiles into metabolic
fluxes
To quantitate metabolic fluxes through the glucose degradation pathways
(Fig. 1) underpinning the metabolite profile shown Table 1, we followed
the flow diagram depicted in Fig. 2.
Conversion of metabolite profiles from relative to quantitative
changes
Metabolite profiling performed under controlled conditions informs relative
changes in metabolites (see Preparation and Perfusion of Mouse Hearts, and
see Section S6 in the Supporting Material). To calculate the fluxes through
the network, effective concentrations (in molar units) of metabolites are
used. Metabolite concentrations are inputs of the rate expressions from
the kinetic model, needed to calculate metabolic fluxes.
The same heart samples that were utilized to perform metabolite
profiling, were analyzed by standard enzymatic assay to determine the
actual concentration of representative metabolites (glucose, glycerol, gluta-
mate, and lactate) present in the profiles. These metabolite concentration
values were used to calibrate the area of the mass spectrometric (MS) peaks
to determine the concentrations of all other metabolites present in the MS
profiles as follows:
Massmetabolite ¼ 1
Mean Areastd=Massstd
 Areametabolite: (4)
Mean Areastd was determined from the area under the peak of the corre-
sponding molecular ion in the mass spectrum. The Massstd was calculated
Metabolomics: relative changes in metabolite levels
Metabolite concentrations
Model build up and optimization of Vmax values
Simulation of the metabolite concentration profile
Fluxome determination
Calculation of fluxome control and regulation
FIGURE 2 Work-flow diagram leading from metabolite profiling to the
fluxome, and the analysis of its control and regulatory properties.
From Metabolomics to Fluxomics 167from the number of moles determined enzymatically in the same samples
that were analyzed by MS multiplied by the mass of the molecular ion.
The moles of metabolite in the sample were calculated according to
Metabolite ðmolÞ ¼ Massmetabolite=MW molecular ion; (5)
where MW stands for molecular weight.
In this procedure, we assume that the area under the peak is proportional
to the mass of the molecular ion impacting the MS detector. The sample
analyzed by MS corresponded to 20 mg wet weight heart tissue. It was
considered that 1 g of wet weight tissue corresponds to 0.42 mL of intracel-
lular water (39).
The metabolite concentrations calculated were used as input data for the
model to optimize Vmax values as described before. After optimization, the
model was utilized to simulate the metabolite concentration profile (Table
1). Another input of our procedure is given by the fluxes of exchange with
the extracellular medium, i.e., rates of oxygen and glucose consumption,
and lactate excretion. These fluxes provide a reference point to estimate
the intracellular fluxes. Specifically for this work, we used rates of O2
consumption reported in How et al. (40).FIGURE 3 Metabolome of glucose utilization pathways obtained from
intact mouse heart perfused with normal glucose. Represented are the
relative metabolite levels detected in hearts perfused with 11 mM glucose
under the conditions described in Materials and Methods (n ¼ 6 hearts).
Metabolites and their corresponding pathways are indicated on the y axis.
The relative scale intensity in the x axis was determined rescaling each
biochemical (n ¼ 6) to set the median equal to 1.0 (Metabolon). (Whiskers
plot) Median and the mean (line and dotwithin the box, respectively), upper
and lower 75 and 25% percentiles of the box. (Dots) Outliers beyond the
whiskers of the plots. To see this figure in color, go online.Preparation and perfusion of mouse hearts
Male wild-type C57BLKS/J-leprþ/leprþ (þ/þ) mice, 8–10 weeks of age,
obtained from Jackson Laboratory (Bar Harbor, ME), were euthanized by
pentobarbital injection following the requirements of the Institutional
Animal Care/Use Committee at Johns Hopkins University, adherent to
National Institutes of Health guidelines. After rapid excision, hearts were
retrogradely perfused (employing the Langendorff technique) with Krebs-
Henseleit buffer, pH 7.4, containing 1.2 mM Pi, 0.5 mM free Mg
2þ,
1.07 mM free Ca2þ, and 11 mM glucose as described in Tocchetti et al.
(9). Hearts were perfused during ~30 min while paced with a pacing
electrode (Radnoti, Monrovia, CA) at 600 bpm (10 Hz, 4 ms duration,
4 V) using a stimulator (Grass Instruments, Quincy, MA).
Vascular tone was assessed through coronary perfusion pressure (CPP)
and LV functionwasmonitoredwith awater-filled, customized latex balloon
inserted in the left ventricle and connected to a P23XL pressure transducer
with interface cable (Harvard Apparatus Instruments, Holliston, MA) and
coupled to a model No. DA100 system (BIOPAC, Santa Barbara, CA) for
continuous data recording and offline analysis. LV end-diastolic pressure
was set at 5–10 mmHg by adjusting the balloon volume with a Gilmont
micrometer syringe (Cole-Parmer, Vernon Hills, IL). The LV-developed
(systolic-diastolic) pressure, CPP (both in mmHg), and maximal rates of
contraction (dP/dtmax) and relaxation (dP/dtmin) (both in mmHg/s) were
determined. After perfusion, hearts were snap-frozen in liquid nitrogen
and sent to Metabolon (Research Triangle Park, NC) for nontargeted metab-
olite profiling (see Section S4 in the Supporting Material).RESULTS
Metabolomics analysis of intact mouse hearts
As a first test of our procedure for translating metabolomics
into fluxomics, we performed metabolite profiling in intact
Langendorff-perfused hearts. Fig. 3 shows the metabolite
profiles from the glucose degradation pathways (Fig. 1) as
determined in mouse hearts superfused with normal
11 mM glucose. Under these conditions, heart functional
variables were (mean5 SE, n¼ 6–11 hearts): LV-developed
pressure (mmHg)¼ 545 6.9; dP/dtmax (mmHg s1)¼ 1545
5 166; dP/dtmin (mmHg s
1) ¼ 1442 5 145; CPP
(mmHg) ¼ 85.85 0.97.Translating metabolite concentrations into
metabolic fluxes
The metabolite profile (relative metabolite changes) shown
in Fig. 3 constitutes the initial departure point leading
to the estimation of metabolite concentration. After opti-
mizing Vmax, we verified that a solution from the solution
space can reproduce the initial metabolite profile by numer-
ical simulation.
Table 1 shows the metabolites concentrations determined
experimentally compared with model simulation. Con-
sidering experimental error, the computational model accu-
rately reproduced metabolite concentrations from the profile
observed experimentally.
Fig. 4 depicts a set of fluxes corresponding to the glucose
catabolic fluxome (in mM s1) exhibited by mouse heartsBiophysical Journal 108(1) 163–172
FIGURE 4 The glucose catabolic fluxome in the
mouse heart. Depicted are the fluxes (shaded
background) next to their respective steps in the
metabolic network of glucose utilization (Fig. 1)
and expressed in mM s1 (equivalent to nmol s1
mL1 intracellular water). The fluxes correspond
to those leading to the metabolite concentrations
that reproduced the ones obtained experimentally
as shown in Table 1 (see also Materials and
Methods). To see this figure in color, go online.
168 Cortassa et al.perfused with glucose only. Displayed is the flux distribu-
tion through glycolysis, immediately upstream and down-
stream of the branch toward the polyol (sorbitol),
glycogenolytic, and PP routes. The mouse heart was able
to sustain a glycolytic flux as high as 41.8 mM s1 upstream
glyceraldehyde 3-phosphate (G3P) (Fig. 4). The PP pathway
sustained a flux that represents 32% of the glycolytic flux
(13.6 mM s1), and is approximately three orders-of-magni-
tude higher than the flux through the polyol pathway
(Fig. 4). The mouse heart is able to utilize internal stores
of glycogen, revealed by glycogenolysis flux values as
high as 36.5 mM s1 under these conditions.
Together, these data reveal that glucose is actively utilized
fromboth the perfusion solution and internal glycogen stores.
Although glucose from glycogen degradation is mainly
broken down via glycolysis, other branching pathways such
as PP and polyols were active, especially the former.Control and regulation of the glucose fluxome
Metabolic control analysis was applied to identify and quan-
tify the control of the flux and metabolite concentrations
from the glucose fluxome determined (Fig. 4).
The main rate-controlling steps of the glycolytic flux
were (Fig. 5 A) as follows: PFKz glycogenolysis (flux con-
trol coefficient, C z 0.65) > ATP demand with negative
control (C ~ 0.4) > Glc uptake (C ~ 0.12) > G6PDH
with negative control (C ¼ 0.05) > HK (C ¼ 0.03).Biophysical Journal 108(1) 163–172A positive control, e.g., C¼ 0.65 for PFK, means that this
enzyme controls 65% of the flux through glycolysis, and
that an increase in the activity of PFK will increase the
glycolytic flux. On the contrary, a negative control, e.g.,
C ¼ 0.05 for G6PDH, implies that this enzyme controls
5% of the flux, and an increase in its activity will actually
decrease the flux through glycolysis.
The control profile of the PP pathway exhibited the same
major rate-controlling steps as glycolysis but with much
higher flux control coefficients (Fig. 5 B): Glycogenolysis
C ¼ 2.2 > ATP demand C ¼ 1.1 (negative) > G6PDH
C ¼ 0.8 > glucose uptake C ¼ 0.4 > HK C ~ 0.1.
The negative control of PFK on PP flux means that any
increase in the flux through glycolysis will have the opposite
effect on the PP flux.
The control profile of the polyol pathway leading to
sorbitol and fructose (Fig. 5 C) displayed a high positive
control by the following steps: ATP demand (C ~ 14) >
glucose uptake (C ~ 2) > aldose reductase (C ¼ 1).
A high negative control was exerted by PFK (C¼13)>
glycogenolysis, HK, G6PDH (C ¼ 1).
Overall, the control of the glucose catabolic fluxome is
highly distributed with glycogenolysis, PFK, and ATP de-
mand as the major rate-controlling steps. The structure of
control reveals that an overall increase in the glycolytic
flux will decrease the flux redirection through PP and poly-
ols, as revealed by the negative flux control exerted via PFK
on both pathways.
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FIGURE 5 Control of the glucose fluxome in the heart. The flux control
coefficients of the most rate-controlling steps of glucose catabolism are
displayed. The bar length indicates the x-axis magnitude of the flux control
coefficient (CC) of glycolysis (A), PP (B), and polyol (C) pathways. The
corresponding enzymatic steps are indicated at the left of each bar plot.
The flux CC can be either positive or negative, and in all cases it was
verified that the sum of the CC ¼ 1.0, in compliance with the summation
theorem.
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The main contribution of this work is to describe a
believed-novel procedure to translate metabolite profiles
(metabolome) into the fluxome, from which the metabolome
originated. Tested with metabolite profiles obtained fromLangendorff-perfused mouse hearts, we were able to quan-
titatively reproduce the metabolite concentration profile
(Table 1) using a set of optimized Vmax values corresponding
to a particular solution from the solution space.
The resulting parameterized computational model was
utilized to calculate the structure of control of the glucose
fluxome comprising all catabolic routes involved in glucose
degradation. The significant control exerted by the ATP
demand is expected from an energy demand-led organ like
the heart. Preceding metabolic control analysis work in the
heart showed that glucose transport and hexokinase were
the most rate-controlling steps of the glycolytic flux (41).
The main differences between our approach and Kashiwaya
et al. (41) are that, in their work, the allosteric property of
PFK was not taken into account, nor was the influence of
ATP and ADP on various enzymatic steps. Including these
regulatory interactions turned out to be important because
PFK exerts a high control on glycolysis and exhibits high
elasticity with respect to ATP and ADP levels.
Thus, the response coefficients of PFK, with respect to
adenine nucleotides, are high and cannot be ignored. That
the ATP demand exerts a negative control on the glycolytic
flux, appears counterintuitive because one would expect that
an increase in energy demand should be followed by an
increase, not a decrease, in glycolysis. However, the nega-
tive control of glycolysis by ATP demand can be explained
according to control by diffuse loops (4,36). In fact, because
PFK is a main rate-controlling step of the glycolytic flux,
and that this enzyme activity depends on ATP thereby
responding positively to its increase, an increase in ATP
demand will decrease ATP availability for PFK activity,
thus yielding lower flux through glycolysis.
Alternative strategies for the quantitative analysis of
metabolomics data have been proposed by Cakmak et al.
(42) and Yizhak et al. (43). Our approach differs from theirs
in the following ways: 1) we use mechanistic rate expres-
sions that account for experimentally demonstrated kinetics
and regulatory interactions; 2) our analytical platform com-
bines existing analytical methods in an integrated manner
for qualitative and quantitative analyses both under steady
and time-dependent conditions; and 3) we are able to trans-
late large metabolite datasets into a functional fluxome that
by accounting for regulatory interactions enables the
computation of the structure of control and regulation of
the biochemical network from which the metabolite profiles
originated.Comparison with experimental data
Quantitative validation of our calculations comes from the
published results of Buchanan et al. (44), who measured
the rate of glycolysis and glucose oxidation in working heart
preparations from wild-type and diabetic (db/db) mice
(Table 2). The equivalent flux measurements in this work
(unloaded Langendorff-perfused heart) corresponded toBiophysical Journal 108(1) 163–172
TABLE 2 Flux values from the literature compared with
fluxome calculations
Tissue source
Flux
reported
mM s1
Flux
estimation
mM s1 Reference
Glycolysis mouse working heart 37.5 41.8 (45)
Glc uptake rat working heart 76.3 9.8 (41)
Glyn utilization rat working heart 7.67 36.5 (41)
Glycolysis mouse working heart 54.17 41.8 (44)
Glc oxidation mouse working heart 5.42 7.79 (44)
G6PDH mouse liver 45.2 13.6 (46)
6PGDH mouse liver 107.2 13.6 (46)
Tkl mouse liver 49.6 4.5 (46)
TAL mouse liver 45.6 4.5 (46,47)
XyDH mouse liver 43.8 0.0031 (47)
SoDH mouse liver 200.9 0.0036 (47)
G6PDH mouse liver 7.55 13.6 (47)
6PGDH mouse liver 6.04 13.6 (47)
Abbreviations are as in Fig. 1. Glyn utilization, glycogen utilization;
XyDH, xylitol dehydrogenase.
170 Cortassa et al.values extrapolated to the y axis (no workload) in Buchanan
et al. (44). These authors found ~1:10 between the glucose
oxidized (~600–700 nmol min1 gram dry weight
(gdw)1) versus glucose catabolized through glycolysis
(~6–7 mmol min1 gdw1). This result agrees very well
with the ratio obtained in our fluxome calculation (Fig. 4).
Considering ~2 mL of intracellular water gdw1 (39), our
calculated pyruvate flux [PEP/Pyr] value of 88.1 mM s1
corresponds to 5.3 mmol glucose min1 gdw1, similar to
the 6–7 mmol min1 gdw1 measured directly in Buchanan
et al. (44). Because different authors report fluxes in various
units, we have translated all values to mM s1 for direct
comparison with our results (Table 2). Kashiwaya et al.
(41) reported values in the same order of magnitude as those
estimated herein, i.e., 76.3 mM s1 (Table 2, rows 2 and 3).
The quantitative discrepancy may be attributed to the differ-
ence in species (mouse versus rat) and physiological condi-
tions (Langendorff versus working heart). However, the
measurement of glycolytic flux in mouse working heart
(also strain C57BL/6) by Dunn et al. (45) rendered a value
of 37.5 mM s1, which closely agrees with our flux estima-
tion. Likewise, for mouse liver and the same enzymes
(G6PDH, P6GDH), different authors (46,47) reported dis-
similar fluxes, but one of them was close to our estimated
fluxes (Table 2).
Because the volume of possible solutions depends on the
choice of objective function to optimize Vmax, further
validation of our procedure will need an independent exper-
imental approach to quantify metabolic fluxes. Table S24
shows Vmax values for a number of reactions to illustrate
how the solution space can change as a function of the opti-
mization criterion. In each case, the values shown in Table
S24 correspond to the vertices of the solutions volume
defined by the sets of maximal Vmax values compatible
with the objective function chosen. Although the maximalBiophysical Journal 108(1) 163–172Vmax of some enzymes varies very little with the change
in objective function, e.g., xylitol dehydrogenase, others
are very sensitive, e.g., glucose transport. Another approach,
by Schuetz et al. (48), performed a thorough evaluation of
different objective functions (linear and nonlinear ones)
with the aim of unraveling the optimization criterion that
rules the metabolic network of, e.g., Escherichia coli
growing in batch or chemostat culture (48), according to
the goodness of the flux prediction.Limitations of this study
Sources of error associated with the flux estimation using
the procedure described herein include variability in the
experimental determination of metabolite concentrations
or reference fluxes (e.g., respiration, lactate secretion). In
the case of metabolites, the results from the matrix
composed by the derivatives of rate expressions with respect
to Vmax, denoted DrV, will be affected (see Eq. S29).
Although controls of recovery with four internal standards
were run during metabolite profiling, quantitation of
metabolite concentrations from metabolomics data may be
subjected to bias due to metabolites extraction and recovery
errors. Regarding reference fluxes, vector b in Eq. 1 will be
influenced. A description of the maximal error associated
with the Vmax estimation based on Savinell and Palsson
(29) is included in Section S3 in the Supporting Material.
When applied to cell populations, metabolomics assumes
an average cell that ignores cellular heterogeneity. In this
sense the metabolite profile represents an average concen-
tration throughout the heart, and only exchanges between
the organ and the perfusion buffer are considered. Thus,
cellular heterogeneity (e.g., cardiomyocytes, fibroblasts)
and compartmentalization are not taken into account.
At this stage, our procedure generates a volume of
possible solutions because the number of unknowns
(Vmax) (m) is larger than the individual metabolite differen-
tial equations (n). Consequently, a unique solution cannot be
determined. A possible way to restrict the solution space
would be through the use of uniform sampling Monte Carlo
methods such as those described in Price et al. (49).CONCLUSIONS
We describe a believed-novel integrated procedure for trans-
lating metabolomics into fluxomics as applied to a highly
dynamic organ such as the heart. This major step forward
has relevant implications for complex metabolic disorders.
Insights gained from applying control analysis to the flux-
ome indicate that glucose oxidation redirection toward
pathways that may restore (e.g., pentose phosphate) or
impair (e.g., polyol) cardiac redox balance, appear to be
crucial for improving type-2 diabetic heart function under
stressful conditions (9). Our methodological approach may
also help in designing therapeutic strategies targeted to
From Metabolomics to Fluxomics 171prevent cardiac dysfunction and, eventually, heart failure in
diabetic patients.SUPPORTING MATERIAL
Supporting Materials and Methods, one figure, twenty-five tables, and
thirty-three equations are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(14)03069-0.
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